Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide in malignant mesothelioma: a phase II study.

M K Andersen1, A Krarup-Hansen, G Mårtensson

  • 1The Department of Oncology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.

Lung Cancer (Amsterdam, Netherlands)
|July 14, 1999
PubMed
Summary

Ifosfamide showed limited efficacy in treating malignant mesothelioma, a rare cancer. The drug caused significant toxicity, including severe leucopenia and neurotoxicity, leading many patients to discontinue treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-promoting and -impeding aspects of using peer-learning during clinical practice education: A qualitative study.

Nurse education in practice·2021
Same author

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).

ESMO open·2021
Same author

A comparative life cycle assessment of stretchable and rigid electronics: a case study of cardiac monitoring devices.

International journal of environmental science and technology : IJEST·2021
Same author

Diagnostic accuracy and interobserver concordance: teledermoscopy of 600 suspicious skin lesions in Southern Denmark.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

A Bayesian method to localize lost gamma sources.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2019
Same author

Genetics of metabolic traits in Greenlanders: lessons from an isolated population.

Journal of internal medicine·2018

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • Malignant mesothelioma is a rare and aggressive cancer with poor prognosis.
  • Limited treatment options exist for unresectable malignant mesothelioma.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of ifosfamide and mesna in patients with unresectable malignant mesothelioma.

Main Methods:

  • A phase II study involving 26 previously untreated patients with histologically proven, unresectable mesothelioma.
  • Patients received ifosfamide 3000 mg/m2/day for 3 days with mesna 1800 mg/m2/day for 3 days every third week.
  • Dose modifications were based on hematologic, neurologic, and renal toxicity.

Main Results:

  • No complete responses were observed; one patient achieved a partial response lasting 25 months.

Related Experiment Videos

  • Disease stabilization occurred in 35% of patients, while 54% progressed.
  • Significant toxicity was noted, including grade 4 leucopenia (50%), grade 3/4 neurotoxicity (38%), and grade 3/4 nausea/vomiting (38%).
  • 42% of patients discontinued treatment due to toxicity.

    • Conclusions:

    • Ifosfamide demonstrated limited clinical activity in malignant mesothelioma at the studied dose.
    • The considerable toxicity profile suggests that ifosfamide may not be a suitable treatment option for this malignancy.